Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)

Biohaven Ltd. (NYSE:BHVN) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s stock price posted a 1.29% year-to-date increase, while it registered a 46.57% decline from a year ago. Based on an analyst consensus by TipRanks, Biohaven has an average price target of $21.44 with a moderate buy rating from analysts.

Top Long-Term Biotechnology Stocks to Buy

In March, Biohaven announced the completion of enrollment in a Phase 2 proof-of-concept (PoC) study with its myostatin-activin pathway inhibitor (MAPI), taldefgrobep alfa, which offers the potential to achieve high-quality weight loss in people living with obesity. It said the topline data from the study are expected in the second half of the year.

Biohaven Senior Vice President of Clinical Development Peter Ackerman, M.D., expressed his excitement for the evaluation of taldefgrobep. He said:

“We believe taldefgrobep could represent an important new agent, as monotherapy and in combination with the current standard of care, that can help optimize high-quality weight loss in people living with obesity. New investigational therapies with novel modes of action are critical to maximizing long-term health benefits in people living with overweight and obesity. While there have been great recent advancements in the field of obesity medicine, there is still a lot of work to do in optimizing the management of a complex, heterogeneous condition that affects nearly half of the world’s population. Our team is grateful to the investigators, their staff, and all participants involved in this important study.”

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology. The company is advancing its innovative therapeutic portfolio, leveraging its proven drug development experience and multiple proprietary drug development platforms.

While we acknowledge the risk and potential of BHVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BHVN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 8 Must-Buy Small Cap Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.